Scotch Plains, NJ, United States of America

Mihirbaran Mandal

This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Sloan-Kettering Institute for Cancer Research, Schering Corporation. Active years: 2009-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mihirbaran Mandal. Retrieved from https://idiyas.com/inventor/mihirbaran-mandal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 66.7

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 45(Granted Patents)

Location History:

New York, NY (US) (2009 - 2012)
Scotch Plains, NJ (US) (2011 - 2015)

Company Filing History:

3 out of 2,405

Merck Sharp + Dohme Corp.

patents

3 out of 519

Sloan-Kettering Institute for Cancer Research

4. 1 out of 834,513

Other

patents

Years Active: 2009-2015

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8957056 - Migrastatin analogs in the treatment of cancer (2015-02-17),

2. 8673900 - Gamma secretase modulators (2014-03-18),

3. 8541427 - Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use (2013-09-24),

4. 8450343 - Gamma secretase modulators (2013-05-28),

5. 8450331 - Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use (2013-05-28),

6. 8188141 - Isomigrastatin analogs in the treatment of cancer (2012-05-29),

7. 8093254 - Aspartyl protease inhibitors (2012-01-10),

8. 7868000 - Aspartyl protease inhibitors (2011-01-11),

9. 7531181 - Gp120 specific antigens and uses thereof (2009-05-12),

Title: Mihirbaran Mandal: Innovator in Cancer Treatment

Introduction

Mihirbaran Mandal is a prominent inventor based in Scotch Plains, NJ (US), known for his significant contributions to cancer research. With a total of nine patents to his name, he has made remarkable strides in developing innovative treatments for various types of cancer.

Latest Patents

Mihirbaran Mandal's latest patents include groundbreaking work on Migrastatin analogs in the treatment of cancer. This invention provides a method for treating colon and/or ovarian cancer by administering a compound that effectively inhibits tumor metastasis. Another notable patent involves gamma secretase modulators, which are novel heterocyclic compounds that can be used in the treatment, prevention, and amelioration of diseases associated with the central nervous system.

Career Highlights

Throughout his career, Mihirbaran Mandal has worked with esteemed organizations such as the Sloan-Kettering Institute for Cancer Research and Merck Sharp & Dohme Corporation. His work in these institutions has allowed him to focus on developing innovative solutions to complex medical challenges.

Collaborations

Mihirbaran has collaborated with notable colleagues, including Zhaoning Zhu and Xiaoxiang Liu, to advance research in his field. Their combined expertise has contributed to the success of various projects and patents.

Conclusion

Mihirbaran Mandal's work exemplifies the spirit of innovation in cancer treatment. His contributions through patents and collaborations continue to pave the way for advancements in medical science.

Profile summary based on public USPTO records.